CV Sciences, Inc.
CV Sciences, Inc. (CVSI): 3 pipeline candidates · ~3 mo cash runway · 18 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.7 months
D/E 3.49 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for CV Sciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8M
Cash
$309K
Quarterly Burn
$1.9M
Runway
2.7 mo
Revenue
$3.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cvsi-007 | Preclinical |
| omnicarbon cardiac valve prosthesis | Approved |
| rls-0071 | Phase 2 |
Frequently asked questions
How many drug candidates are in CV Sciences, Inc.'s pipeline?
CV Sciences, Inc. (CVSI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CV Sciences, Inc.'s lead drug candidate?
CV Sciences, Inc.'s most advanced tracked candidate is cvsi-007 (Preclinical) for smokeless tobacco use and addiction.
What is CV Sciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CV Sciences, Inc. has approximately 2.7 months of cash runway.
What is CV Sciences, Inc.'s market capitalization?
CV Sciences, Inc.'s market capitalization is approximately $3.8M.
Who is the CEO of CV Sciences, Inc.?
Mr. Joseph D. Dowling is the chief executive officer of CV Sciences, Inc. (CVSI).
Get the full picture on CV Sciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.